A detailed history of R Squared LTD transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, R Squared LTD holds 580 shares of DNLI stock, worth $13,519. This represents 0.01% of its overall portfolio holdings.

Number of Shares
580
Holding current value
$13,519
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$20.24 - $31.58 $11,739 - $18,316
580 New
580 $11.8 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.13B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track R Squared LTD Portfolio

Follow R Squared LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of R Squared LTD, based on Form 13F filings with the SEC.

News

Stay updated on R Squared LTD with notifications on news.